...
首页> 外文期刊>American Journal of Physiology >Rethinking glomerular basement membrane thickening in diabetic nephropathy: adaptive or pathogenic?
【24h】

Rethinking glomerular basement membrane thickening in diabetic nephropathy: adaptive or pathogenic?

机译:重新思考糖尿病肾病中的肾小球基底膜增厚:适应性或致病性?

获取原文
获取原文并翻译 | 示例

摘要

Diabetic nephropathy (DN) is the leading cause of chronic kidney disease in the United States and is a major cause of cardiovascular disease and death. DN develops insidiously over a span of years before clinical manifestations, including microalbu-minuria and declining glomerular filtration rate (GFR), are evident. During the clinically silent period, structural lesions develop, including glomerular basement membrane (GBM) thickening, mesangial expansion, and glomerulosclerosis. Once microalbuminuria is clinically apparent, structural lesions are often considerably advanced, and GFR decline may then proceed rapidly toward end-stage kidney disease. Given the current lack of sensitive biomarkers for detecting early DN, a shift in focus toward examining the cellular and molecular basis for the earliest structural change in DN, i.e., GBM thickening, may be warranted. Observed within one to two years following the onset of diabetes, GBM thickening precedes clinically evident albuminuria. In the mature glomerulus, the podocyte is likely key in modifying the GBM, synthesizing and assembling matrix components, both in physiological and pathological states. Podocytes also secrete matrix metalloprotei-nases, crucial mediators in extracellular matrix turnover. Studies have shown that the critical podocyte-GBM interface is disrupted in the diabetic milieu. Just as healthy podocytes are essential for maintaining the normal GBM structure and function, injured podocytes likely have a fundamental role in upsetting the balance between the GBM's synthetic and degradative pathways. This article will explore the biological significance of GBM thickening in DN by reviewing what is known about the GBM's formation, its maintenance during health, and its disruption in DN.
机译:糖尿病肾病(DN)是美国慢性肾病的主要原因,是心血管疾病和死亡的主要原因。在临床表现前的多年内,DN在临床表现(包括微肺腹和肾小球过滤率下降)(GFR)中发育不到多年来,显而易见。在临床静脉期间,结构病变发生,包括肾小球基底膜(GBM)增厚,梭菌膨胀和肾小球粥样硬化。一旦微白蛋白尿是临床上明显的,结构病变通常很大,并且GFR下降可以迅速朝着终级肾脏疾病进行。鉴于当前缺乏用于检测早期DN的敏感生物标志物,可以保证重点朝向检查DN的最早结构变化的细胞和分子基础的转变,即GBM增厚。在糖尿病发作后一到两年内观察到,GBM增厚在临床上明显的亲蛋白尿。在成熟的肾小球中,密码细胞可能是在生理和病理状态下改变GBM,合成和组装基质组分的关键。平粒细胞还分泌基质金属蛋白酶,细胞外基质周转中的关键介质。研究表明,临界大致细胞-GBM界面在糖尿病Milieu中断。正如健康的哆哆ytes对维持正常的GBM结构和功能是必不可少的,受伤的哆粒细胞可能在扰乱GBM合成和降解途径之间的平衡方面具有基本作用。本文将通过审查GBM的形成,其在健康期间的维护以及其在DN中的破坏来探讨DN中GBM增厚的生物学意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号